Company Overview

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision oncology therapies for genetically defined cancers with high unmet medical need. The company operates within the biotechnology and pharmaceutical research industries, with an emphasis on targeted small-molecule drugs designed to inhibit oncogenic drivers identified through molecular profiling.

Kura’s primary value drivers are its clinical development programs, most notably its menin inhibitor and farnesyltransferase inhibitor platforms. The company’s strategy centers on precision medicine approaches that align specific therapies with well-characterized genetic alterations in cancer. Founded in 2014, Kura Oncology evolved from early discovery-stage research into a late clinical-stage company, advancing multiple assets into mid- and late-stage clinical trials and establishing partnerships to accelerate development and commercialization.

Business Operations

Kura Oncology generates value through the research, development, and clinical advancement of oncology drug candidates rather than through commercial product sales. Its core operating segments are its drug discovery and development programs, with resources allocated primarily to clinical trials, regulatory activities, and supporting translational research. As a clinical-stage company, revenue historically consists mainly of collaboration payments and licensing-related income rather than product sales.

The company’s lead assets include ziftomenib, a menin inhibitor being developed for genetically defined subsets of acute myeloid leukemia, and tipifarnib, a farnesyltransferase inhibitor targeting HRAS-mutant solid tumors. Kura conducts clinical operations primarily through contracted clinical research organizations and maintains intellectual property ownership over its core technologies. It operates without manufacturing facilities, relying on third-party manufacturers and development partners for clinical supply.

Strategic Position & Investments

Kura Oncology’s strategic direction is centered on becoming a leader in precision oncology, particularly in hematologic malignancies driven by defined molecular alterations. A major growth initiative is the advancement of ziftomenib through late-stage clinical development, including combination strategies and expansion into additional genetically defined patient populations.

The company has pursued selective partnerships to enhance development capabilities and extend its clinical reach, including global collaboration arrangements to support regulatory and commercialization pathways. Kura continues to invest in pipeline expansion through internal research and early-stage development, focusing on emerging targets within epigenetic regulation and oncogenic signaling pathways. No large-scale diversified portfolio investments have been disclosed, as capital allocation remains focused on advancing its core clinical assets.

Geographic Footprint

Kura Oncology is headquartered in San Diego, California, a major biotechnology hub in the United States. Its executive leadership, research oversight, and corporate functions are primarily based at this location.

While its physical operations are U.S.-centered, Kura maintains a global clinical presence through international clinical trial sites across North America, Europe, and other regions, reflecting the multinational nature of oncology drug development. The company’s international footprint is primarily operational rather than commercial, as it does not yet market approved products.

Leadership & Governance

Kura Oncology was co-founded by experienced biotechnology executives with backgrounds in oncology drug development. The company’s leadership emphasizes scientific rigor, disciplined capital allocation, and precision medicine-driven strategy, with governance structured to support long-term clinical and regulatory execution.

Key executives include:

• Troy Wilson – President and Chief Executive Officer
• David Kirn – Chief Medical Officer
• Thomas Doyle – Chief Financial Officer
• Brian Wilkinson – Chief Operating Officer
• Aaron Schimmer – Executive Vice President, Research and Development

The board and management team collectively bring experience from large pharmaceutical companies and emerging biotech firms, guiding Kura’s focus on advancing differentiated oncology therapies through clinically meaningful milestones.